Search

Your search keyword '"Wendum, D"' showing total 312 results
Start Over Author "Wendum, D"
312 results on '"Wendum, D"'

1. AB0033 LIVER DISEASE COMPLICATING FAMILIAL MEDITERRANEAN FEVER: A STUDY ON 57 PATIENTS FROM THE FRENCH ADULT JIR COHORT

Author

Delplanque, M., primary, Amiot, X., additional, Wendum, D., additional, Rodrigues, F., additional, Bourguiba, R., additional, Aknouche, Z., additional, Terris, B., additional, Duvoux, C., additional, Bedossa, P., additional, Lebrec, D., additional, Sogni, P., additional, Perlati, L., additional, Charlotte, F., additional, Ratziu, V., additional, Augustin, J., additional, Calderaro, J., additional, Scoazec, G., additional, Vignaud, J. M., additional, Sevrig, J. A., additional, Grateau, G., additional, Savey, L., additional, and Georgin-Lavialle, S., additional

Published
2024
Full Text
View/download PDF

2. Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)

Author

Salmon, D., Usubillaga, R., Sogni, P., Terris, B., Tremeaux, P., Katlama, C., Valantin, M.A., Stitou, H., Simon, A., Cacoub, P., Nafissa, S., Benhamou, Y., Charlotte, F., Fourati, Virologie: S., Poizot-Martin, I., Zaegel, O., Laroche, H., Tamalet, C., Pialoux, G., Chas, J., Callard, P., Bendjaballah, F., Amiel, C., Le Pendeven, C., Marchou, B., Alric, L., Barange, K., Metivier, S., Selves, J., Larroquette, F., Rosenthal, E., Infectiologie, Naqvi, A., Rio, V., Haudebourg, J., Saint-Paul, M.C., Monte, A. De, Giordanengo, V., Partouche, C., Bouchaud, O., Martin, A., Ziol, M., Baazia, Y., Iwaka-Bande, V., Gerber, A., Uzan, M., Bicart-See, A., Garipuy, D., Ferro-Collados, M.J., Virologie, Nicot, F., Gervais, A., Yazdanpanah, Y., Adle-Biassette, H., Alexandre, G., Peytavin, G., Lascoux-Combe, C., Molina, J.M., Bertheau, P., Chaix, M.L., Delaugerre, C., Maylin, S., Lacombe, K., Bottero, J., Krause, J., Girard, P.M., Wendum, D., Cervera, P., Adam, J., Viala, C., Vittecocq, D., Goujard, C., Quertainmont, Y., Teicher, E., Pallier, C., Lortholary, O., Duvivier, C., Rouzaud, C., Lourenco, J., Touam, F., Louisin, C., Avettand-Fenoel, V., Gardiennet, E., Mélard, A., Neau, D., Ochoa, A., Blanchard, E., Castet-Lafarie, S., Cazanave, C., Malvy, D., Dupon, M., Dutronc, H., Dauchy, F., Lacaze-Buzy, L., Desclaux, A., Bioulac-Sage, P., Trimoulet, P., Reigadas, S., Morlat, P., Lacoste, D., Bonnet, F., Bernard, N., Hessamfar, M., J, Paccalin, F., Martell, C., Pertusa, M.C., Vandenhende, M., Mercié, P., Pistone, T., Receveur, M.C., Méchain, M., Duffau, P., Rivoisy, C., Faure, I., Caldato, S., Bellecave, P., Tumiotto, C., Pellegrin, J.L., Viallard, J.F., Lazzaro, E., Greib, C., Zucman, D., Majerholc, C., Brollo, M., Farfour, E., Boué, F., Devoto, J. Polo, Kansau, I., Chambrin, V., Pignon, C., Berroukeche, L., Fior, R., Martinez, V., Abgrall, S., Favier, M., Deback, C., Lévy, Y., Dominguez, S., Lelièvre, J.D., Lascaux, A.S., Melica, G., Billaud, E., Raffi, F., Allavena, C., Reliquet, V., Boutoille, D., Biron, C., Lefebvre, M., Hall, N., Bouchez, S., Rodallec, A., Le Guen, L., Hemon, C., Miailhes, P., Peyramond, D., Chidiac, C., Ader, F., Biron, F., Boibieux, A., Cotte, L., Ferry, T., Perpoint, T., Koffi, J., Zoulim, F., Bailly, F., Lack, P., Maynard, M., Radenne, S., Amiri, M., Valour, F., Augustin-Normand, C., Scholtes, C., Le-Thi, T.T., Piroth, L., Chavanet, P., Duong Van Huyen, M., Buisson, M., Waldner-Combernoux, A., Mahy, S., Salmon Rousseau, A., Martins, C., Aumaître, H., Galim, S., Bani-Sadr, F., Lambert, D., Nguyen, Y., Berger, J.L., Hentzien, M., Brodard, V., Rey, D., Partisani, M., Batard, M.L., Cheneau, C., Priester, M., Bernard-Henry, C., de Mautort, E., Fischer, P., Gantner, P., Fafi-Kremer, S., Roustant, F., Platterier, P., Kmiec, I., Traore, L., Lepuil, S., Parlier, S., Sicart-Payssan, V., Bedel, E., Anriamiandrisoa, S., Pomes, C., Mole, M., Bolliot, C., Catalan, P., Mebarki, M., Adda-Lievin, A., Thilbaut, P., Ousidhoum, Y., Makhoukhi, F.Z., Braik, O., Bayoud, R., Gatey, C., Pietri, M.P., Le Baut, V., Ben Rayana, R., Bornarel, D., Chesnel, C., Beniken, D., Pauchard, M., Akel, S., Lions, C., Ivanova, A., Ritleg, A.-S., Debreux, C., Chalal, L., Zelie, J., Hue, H., Soria, A., Cavellec, M., Breau, S., Joulie, A., Fisher, P., Gohier, S., Croisier-Bertin, D., Ogoudjobi, S., Brochier, C., Thoirain-Galvan, V., Le Cam, M., Wittkop, L., Esterle, L., Izopet, J., Serfaty, L., Paradis, V., Spire, B., Carrieri, P., Zaegel-Faucher, O., Meyer, L., Boufassa, F., Autran, B., Roque, A.M., Solas, C., Fontaine, H., Costagliola, D., Petrov-Sanchez, V., Levier, A., P. Carrieri, Chalouni, M., Conte, V., Dequae-Merchadou, L., Desvallées, M., Gilbert, C., Gillet, S., Guillochon, Q., Khan, C., Knight, R., Marcellin, F., Michel, L., Mora, M., Protopopescu, C., Roux, P., Barré, T., Ramier, C., Sow, A., Di Beo, V., Bureau, M., Marcellin, Fabienne, Brégigeon-Ronot, Sylvie, Ramier, Clémence, Protopopescu, Camelia, Gilbert, Camille, Di Beo, Vincent, Duvivier, Claudine, Bureau-Stoltmann, Morgane, Rosenthal, Eric, Wittkop, Linda, Salmon-Céron, Dominique, Carrieri, Patrizia, Sogni, Philippe, and Barré, Tangui

Published
2023
Full Text
View/download PDF

3. Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus‐co‐infected patients (ANRS CO13‐HEPAVIH)

Author

Nordmann, S., Vilotitch, A., Roux, P., Esterle, L., Spire, B., Marcellin, F., Salmon‐Ceron, D., Dabis, F., Chas, J., Rey, D., Wittkop, L., Sogni, P., Carrieri, P., Salmon, D, Trimoulet, P, Izopet, J, Serfaty, L, Paradis, V, Valantin, M.A., Pialoux, G, Poizot‐Martin, I, Barange, K, Naqvi, A, Rosenthal, E, Bicart‐See, A, Bouchaud, O, Gervais, A, Lascoux‐Combe, C, Goujard, C, Lacombe, K, Duvivier, C, Vittecoq, D, Neau, D, Morlat, P, Bani‐Sadr, F, Meyer, L, Boufassa, F, Dominguez, S, Autran, B, Roque, A.M., Solas, C, Fontaine, H, Costagliola, D, Piroth, L, Simon, A, Zucman, D, Boué, F, Miailhes, P, Billaud, E, Aumaître, H, Couffin‐Cadiergues, S, Marchand, L, Salmon, D, Alagna, L, Sogni, P, Terris, B, Krivine, A, Katlama, C, Valantin, M.A., Stitou, H, Benhamou, Y, Charlotte, F, Fourati, S, Simon, A, Cacoub, P, Nafissa, S, Poizot‐Martin, I, Zaegel, O, Porcher, M, Tamalet, C, Pialoux, G, Chas, J, Slama, L, Callard, P, Bendjaballah, F, Le Pendeven, C, Marchou, B, Alric, L, Barange, K, Metivier, S, Selves, J, Larroquette, F, Rosenthal, E, Haudebourg, J, Saint‐Paul, M.C., Partouche, C, Bouchaud, O, Ziol, M, Baazia, Y, Uzan, M, Bicart‐See, A, Garipuy, D, Ferro‐Collados, M.J, Selves, J, Nicot, F, Gervais, A, Yazdanpanah, Y, Adle‐Biassette, H, Alexandre, G, Lascoux‐Combe, C, Molina, J.M, Bertheau, P, Duclos, J, Palmer, P, Lacombe, K, Campa, P, Girard, P.M, Wendum, D, Cervera, P, Adam, J, Viala, C, Goujard, C, Pallier, C, Vittecoq, D, Lortholary, O, Duvivier, C, Shoai‐Tehrani, M, Mélard, A, Neau, D, Ochoa, A, Blanchard, E, Castet‐Lafarie, S, Cazanave, C, Malvy, D, Dupon, M, Dutronc, H, Dauchy, F, Lacaze‐Buzy, L, Bioulac‐Sage, P, Trimoulet, P, Reigadas, S, Morlat, P, Lacoste, D, Bonnet, F, Bernard, N, Bonarek Hessamfar, M, Roger‐Schmeltz, J, Gellie, P, Thibaut, P, Paccalin, F, Martell, C, Carmen Pertusa, M, Vandenhende, M, Mercier, P, Malvy, D, Pistone, T, Receveur, M.C, Caldato, S, Bioulac‐Sage, P, Trimoulet, P, Reigadas, S, Pellegrin, J.L, Viallard, J.F, Lazzaro, E, Greib, C, Bioulac‐Sage, P, Trimoulet, P, Reigadas, S, Zucman, D, Majerholc, C, Guitard, F, Boué, F, Polo Devoto, J, Kansau, I, Chambrin, V, Pignon, C, Berroukeche, L, Fior, R, Martinez, V, Deback, C, Lévy, Y, Dominguez, S, Lelièvre, J.D, Lascaux, A.S, Melica, G, Billaud, E, Raffi, F, Alavena, C, Rodallec, A, Miailhes, P, Peyramond, D, Chidiac, C, Ader, F, Biron, F, Boibieux, A, Cotte, L, Ferry, T, Perpoint, T, Koffi, J, Zoulim, F, Bailly, F, Lack, P, Maynard, M, Radenne, S, Amiri, M, Le‐Thi, T.T, Piroth, L, Chavanet, P, Duong Van Huyen, M, Buisson, M, Waldner‐Combernoux, A, Mahy, S, Binois, R, Simonet‐Lann, A.L, Croisier‐Bertin, D, Aumaître, H, Bani‐Sadr, F, Lambert, D, Nguen, Y, Rouger, C, Berger, J.L, Partrisiani, M, Gautner, P, Batard, M.L, Beniken, D, Lupin, C, Lions, C, Ritleng, A.‐S, Honoré, P, Payssan, V, Breau, S, Joulie, A, Mole, M, Bolliot, C, Touam, F, André, F, Hue, H, Larmet, L, Brochier, C, Thoirain, V, Raho‐Moussa, M, Ogoudjobi, S, Azar, M, Bornarel, D, Gohier, S, Chesnel, C, Maradan, G, Kurkdji, P, Hadjoudj, S, Malet, M, Kmiec, I, Fischer, P, Palacin, A, Pietri, M.P, Le Baut, V, Guet, P, Le Puil, S, Mebarki, M, Fior, A, Adda‐Lievin, A, Conte, V, Delaune, J, Dequae Merchadou, L, Douiri, N, Gillet, S, Gilbert, C, Jacquet, A, Kherraz, R, Lagorse, P, Mora, M, Protopopescu, C, and Rosellini, S

Published
2018
Full Text
View/download PDF

5. Post‐HCV cure self‐reported changes in physical activity, eating behaviours, and fatigue in people living with HIV (ANRS CO13 HEPAVIH)

Author

Marcellin, Fabienne, Di Beo, Vincent, Esterle, Laure, Abgrall, Sophie, Pialoux, Gilles, Barré, Tangui, Wittkop, Linda, Salmon‐ceron, Dominique, Sogni, Philippe, Carrieri, Patrizia, Roustant, F, Platterier, P, Kmiec, I, Traore, L, Lepuil, S, Parlier, S, Sicart‐payssan, V, Bedel, E, Anriamiandrisoa, S, Pomes, C, Mole, M, Bolliot, C, Catalan, P, Mebarki, M, Adda‐lievin, A, Thilbaut, P, Ousidhoum, Y, Makhoukhi, F.Z, Braik, O, Bayoud, R, Gatey, C, Pietri, M.P, Le Baut, V, Ben Rayana, R, Bornarel, D, Chesnel, C, Beniken, D, Pauchard, M, Akel, S, Lions, C, Ivanova, A, Ritleg, A‐s, Debreux, C, Chalal, L, Zelie, J, Hue, H, Soria, A, Cavellec, M, Breau, S, Joulie, A, Fisher, P, Gohier, S, Croisier‐bertin, D, Ogoudjobi, S, Brochier, C, Thoirain‐galvan, V, Le Cam, M, Chalouni, M, Conte, V, Dequae‐merchadou, L, Desvallees, M, Gilbert, C, Gillet, S, Knight, R, Lemboub, T, Michel, L, Mora, M, Protopopescu, C, Roux, P, Tezkratt, S, Ramier, C, Sow, A, Bureau, M, Trimoulet, P, Izopet, J, Serfaty, L, Paradis, V, Spire, B, Valantin, V., Chas, J, Zaegel‐faucher, O, Barange, K, Naqvi, A, Rosenthal, E, Bicart‐see, A, Bouchaud, O, Gervais, A, Lascoux‐combe, C, Goujard, C, Lacombe, K, Duvivier, C, Neau, D, Morlat, P, Bani‐sadr, F, Meyer, L, Boufassa, F, Autran, B, Roque, A.M, Solas, C, Fontaine, H, Costagliola, D, Piroth, L, Simon, A, Zucman, D, Boué, F, Miailhes, P, Billaud, E, Aumaître, H, Rey, D, Peytavin, G, Petrov‐sanchez, V, Levier, A, Usubillaga, R., Terris, B, Tremeaux, P, Katlama, C, Stitou, H, Cacoub, P, Nafissa, S, Benhamou, Y, Charlotte, F, Fourati, S, Poizot‐martin, I, Zaegel, O, Laroche, H, Tamalet, C, Callard, P, Bendjaballah, F, Amiel, C, Le Pendeven, C, Marchou, B, Alric, L, Metivier, S, Selves, J, Larroquette, F, Rio, V, Haudebourg, J, Saint‐paul, M.C, de Monte, A, Giordanengo, V, Partouche, C, Martin, A, Ziol, M, Baazia, Y, Iwaka‐bande, V, Gerber, A, Uzan, M, Garipuy, D, Ferro‐collados, M.J, Nicot, F, Yazdanpanah, Y, Adle‐biassette, H, Alexandre, G, Molina, J.M, Bertheau, P, Chaix, M.L, Delaugerre, C, Maylin, S, Bottero, J, Krause, J, Girard, P.M, Wendum, D, Cervera, P, Adam, J, Viala, C, Vittecocq, D, Quertainmont, Y, Teicher, E, Pallier, C, Lortholary, O, Rouzaud, C, Lourenco, J, Touam, F, Louisin, C, Avettand‐fenoel, V, Gardiennet, E, Mélard, A, Ochoa, A, Blanchard, E, Castet‐lafarie, S, Cazanave, C, Malvy, D, Dupon, M, Dutronc, H, Dauchy, F, Lacaze‐buzy, L, Desclaux, A, Bioulac‐sage, P, Reigadas, S, Lacoste, D, Bonnet, F, Bernard, N, Hessamfar, M, Paccalin, J.F, Martell, C, Pertusa, M.C, Vandenhende, M, Mercié, P, Pistone, T, Receveur, M.C, Méchain, M, Duffau, P, Rivoisy, C, Faure, I, Caldato, S, Bellecave, P, Tumiotto, C, Pellegrin, J.L, Viallard, J.F, Lazzaro, E, Greib, C, Majerholc, C, Brollo, M, Farfour, E, Polo Devoto, J, Kansau, I, Chambrin, V, Pignon, C, Berroukeche, L, Fior, R, Martinez, V, Favier, M, Deback, C, Lévy, Y, Dominguez, S, Lelièvre, J.D, Lascaux, A.S, Melica, G, Raffi, F, Allavena, C, Reliquet, V, Boutoille, D, Biron, C, Lefebvre, M, Hall, N, Bouchez, S, Rodallec, A, Le Guen, L, Hemon, C, Peyramond, D, Chidiac, C, Ader, F, Biron, F, Boibieux, A, Cotte, L, Ferry, T, Perpoint, T, Koffi, J, Zoulim, F, Bailly, F, Lack, P, Maynard, M, Radenne, S, Amiri, M, Valour, F, Augustin‐normand, C, Scholtes, C, Le‐thi, T.T, Chavanet, P, Duong van Huyen, M, Buisson, M, Waldner‐combernoux, A, Mahy, S, Salmon Rousseau, A, Martins, C, Galim, S, Lambert, D, Nguyen, Y, Berger, J.L, Hentzien, M, Brodard, V, Partisani, M, Batard, M.L, Cheneau, C, Priester, M, Bernard‐henry, C, de Mautort, E, Fischer, P, Gantner, P, Fafi‐kremer, S, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des sciences de la santé publique [Marseille] (ISSPAM), Team MORPH3EUS (INSERM U1219 - UB - ISPED), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, AP-HP - Hôpital Antoine Béclère [Clamart], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Bordeaux [Bordeaux], Hôpital Cochin [AP-HP], Université Paris Descartes - Paris 5 (UPD5), Physiopathologie du système immunitaire (Inserm U1223), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), ANRS CO13 HEPAVIH Study Group: F Roustant, P Platterier, I Kmiec, L Traore, S Lepuil, S Parlier, V Sicart-Payssan, E Bedel, S Anriamiandrisoa, C Pomes, M Mole, C Bolliot, P Catalan, M Mebarki, A Adda-Lievin, P Thilbaut, Y Ousidhoum, F Z Makhoukhi, O Braik, R Bayoud, C Gatey, M P Pietri, V Le Baut, R Ben Rayana, D Bornarel, C Chesnel, D Beniken, M Pauchard, S Akel, C Lions, A Ivanova, A-S Ritleg, C Debreux, L Chalal, J Zelie, H Hue, A Soria, M Cavellec, S Breau, A Joulie, P Fisher, S Gohier, D Croisier-Bertin, S Ogoudjobi, C Brochier, V Thoirain-Galvan, M Le Cam, M Chalouni, V Conte, L Dequae-Merchadou, M Desvallees, C Gilbert, S Gillet, R Knight, T Lemboub, L Michel, M Mora, C Protopopescu, P Roux, S Tezkratt, C Ramier, A Sow, M Bureau, P Trimoulet, J Izopet, L Serfaty, V Paradis, B Spire, Valantin, J Chas, O Zaegel-Faucher, K Barange, A Naqvi, E Rosenthal, A Bicart-See, O Bouchaud, A Gervais, C Lascoux-Combe, C Goujard, K Lacombe, C Duvivier, D Neau, P Morlat, F Bani-Sadr, L Meyer, F Boufassa, B Autran, A M Roque, C Solas, H Fontaine, D Costagliola, L Piroth, A Simon, D Zucman, F Boué, P Miailhes, E Billaud, H Aumaître, D Rey, G Peytavin, V Petrov-Sanchez, A Levier, R Usubillaga, B Terris, P Tremeaux, C Katlama, H Stitou, P Cacoub, S Nafissa, Y Benhamou, F Charlotte, S Fourati, I Poizot-Martin, O Zaegel, H Laroche, C Tamalet, P Callard, F Bendjaballah, C Amiel, C Le Pendeven, B Marchou, L Alric, S Metivier, J Selves, F Larroquette, V Rio, J Haudebourg, M C Saint-Paul, A De Monte, V Giordanengo, C Partouche, A Martin, M Ziol, Y Baazia, V Iwaka-Bande, A Gerber, M Uzan, D Garipuy, M J Ferro-Collados, J Selves, F Nicot, Y Yazdanpanah, H Adle-Biassette, G Alexandre, J M Molina, P Bertheau, M L Chaix, C Delaugerre, S Maylin, J Bottero, J Krause, P M Girard, D Wendum, P Cervera, J Adam, C Viala, D Vittecocq, Y Quertainmont, E Teicher, C Pallier, O Lortholary, C Rouzaud, J Lourenco, F Touam, C Louisin, V Avettand-Fenoel, E Gardiennet, A Mélard, A Ochoa, E Blanchard, S Castet-Lafarie, C Cazanave, D Malvy, M Dupon, H Dutronc, F Dauchy, L Lacaze-Buzy, A Desclaux, P Bioulac-Sage, S Reigadas, D Lacoste, F Bonnet, N Bernard, M Hessamfar, J F Paccalin, C Martell, M C Pertusa, M Vandenhende, P Mercié, D Malvy, T Pistone, M C Receveur, M Méchain, P Duffau, C Rivoisy, I Faure, S Caldato, P Bioulac-Sage, S Reigadas, P Bellecave, C Tumiotto, J L Pellegrin, J F Viallard, E Lazzaro, C Greib, P Bioulac-Sage, S Reigadas, C Majerholc, M Brollo, E Farfour, J Polo Devoto, I Kansau, V Chambrin, C Pignon, L Berroukeche, R Fior, V Martinez, M Favier, C Deback, Y Lévy, S Dominguez, J D Lelièvre, A S Lascaux, G Melica, F Raffi, C Allavena, V Reliquet, D Boutoille, C Biron, M Lefebvre, N Hall, S Bouchez, A Rodallec, L Le Guen, C Hemon, D Peyramond, C Chidiac, F Ader, F Biron, A Boibieux, L Cotte, T Ferry, T Perpoint, J Koffi, F Zoulim, F Bailly, P Lack, M Maynard, S Radenne, M Amiri, F Valour, J Koffi, F Zoulim, F Bailly, P Lack, M Maynard, S Radenne, C Augustin-Normand, C Scholtes, T T Le-Thi, P Chavanet, M Duong Van Huyen, M Buisson, A Waldner-Combernoux, S Mahy, A Salmon Rousseau, C Martins, S Galim, D Lambert, Y Nguyen, J L Berger, M Hentzien, V Brodard, M Partisani, M L Batard, C Cheneau, M Priester, C Bernard-Henry, E de Mautort, P Fischer, P Gantner, S Fafi-Kremer, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris], Statistics In System biology and Translational Medicine (SISTM), Inria Bordeaux - Sud-Ouest, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)- Bordeaux population health (BPH), and Malbec, Odile

Subjects
0303 health sciences, Hepatology, business.industry, [SDV]Life Sciences [q-bio], Human immunodeficiency virus (HIV), MEDLINE, Physical activity, medicine.disease_cause, 3. Good health, [SDV] Life Sciences [q-bio], 03 medical and health sciences, 0302 clinical medicine, Infectious Diseases, Virology, Medicine, 030211 gastroenterology & hepatology, business, Eating behaviour, ComputingMilieux_MISCELLANEOUS, 030304 developmental biology, Clinical psychology
Abstract

International audience; No abstract available

Published
2021

6. A placebo-controlled randomised trial of budesonide for primary biliary cholangitis following an insufficient response to UDCA

Author

Hirschfield, G.M, Beuers, U., Kupcinskas, L., Ott, P., Bergquist, A., Färkkilä, M., Manns, M. P, Pares, A., Spengler, U., Stiess, M, Greinwald, R., Pröls, M, Wendum, D, Drebber, U, and Poupon, R.

Abstract

Background & Aims: In patients with primary biliary cholangitis (PBC) the utility of budesonide, a synthetic corticosteroid displaying high first-pass metabolism, is unresolved. In a placebo-controlled, double-blind trial, we evaluated the added-value of budesonide in those with PBC and ongoing risk of progressive disease despite ursodeoxycholic acid (UDCA). Methods: We evaluated 62 patients with PBC who had histologically confirmed hepatic inflammatory activity, according to the Ishak-score, and an alkaline phosphatase (ALP) >1.5x upper limit of normal (ULN), after at least 6 months of UDCA therapy. Participants were randomly assigned 2:1 to receive budesonide (9 mg/day) or placebo once daily, for 36 months, with UDCA treatment (12-16 mg/kg body weight/day) maintained. Primary efficacy was defined as improvement of liver histology with respect to inflammation and no progression of fibrosis. Secondary outcomes included changes in biochemical markers of liver injury. Results: Recruitment challenges resulted in a study underpowered compared to original intent. The primary histologic endpoint, comparing patients with paired biopsies only (n= 43), was not met (p>0.05). The proportion of patients with ALP

Published
2021

9. Immunohistochemical analysis of adenocarcinoma of the small intestine: a tissue microarray study

Author

Svrcek, M., Jourdan, F., Sebbagh, N., Couvelard, A., Chatelain, D., Mourra, N., Olschwang, S., Wendum, D., and Flejou, J.-F.

Subjects
Health
Abstract

J Clin Pathol 2003;56:898-903 Background: Primary adenocarcinomas of the small intestine are rare, and the genetic mechanisms involved in their carcinogenesis remain unclear. Aim: To examine the expression of candidate [...]

Published
2003

12. Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)

Author

Marcellin, Fabienne, primary, Di Beo, Vincent, additional, Aumaitre, Hugues, additional, Mora, Marion, additional, Wittkop, Linda, additional, Duvivier, Claudine, additional, Protopopescu, Camelia, additional, Lacombe, Karine, additional, Esterle, Laure, additional, Berenger, Cyril, additional, Gilbert, Camille, additional, Bouchaud, Olivier, additional, Poizot-Martin, Isabelle, additional, Sogni, Philippe, additional, Salmon-Ceron, Dominique, additional, Carrieri, Patrizia, additional, Salmon, D., additional, Wittkop, L., additional, Sogni, P., additional, Esterle, L., additional, Trimoulet, P., additional, Izopet, J., additional, Serfaty, L., additional, Paradis, V., additional, Spire, B., additional, Carrieri, P., additional, Valantin, M.A., additional, Pialoux, G., additional, Chas, J., additional, Poizot-Martin, I., additional, Barange, K., additional, Naqvi, A., additional, Rosenthal, E., additional, Bicart-See, A., additional, Bouchaud, O., additional, Gervais, A., additional, Lascoux-Combe, C., additional, Goujard, C., additional, Lacombe, K., additional, Duvivier, C., additional, Neau, D., additional, Morlat, P., additional, Bani-Sadr, F., additional, Meyer, L., additional, Boufassa, F., additional, Autran, B., additional, Roque, A.M., additional, Solas, C., additional, Fontaine, H., additional, Costagliola, D., additional, Piroth, L., additional, Simon, A., additional, Zucman, D., additional, Boué, F., additional, Miailhes, P., additional, Billaud, E., additional, Aumaître, H., additional, Rey, D., additional, Peytavin, G., additional, Petrov-Sanchez, V., additional, Lebrasseur-Longuet, D., additional, Usubillaga, R., additional, Terris, B., additional, Tremeaux, P., additional, Katlama, C., additional, Stitou, H., additional, Cacoub, P., additional, Nafissa, S., additional, Benhamou, Y., additional, Charlotte, F., additional, Fourati, S., additional, Zaegel, O., additional, Laroche, H., additional, Tamalet, C., additional, Callard, P., additional, Bendjaballah, F., additional, Amiel, C., additional, Le Pendeven, C., additional, Marchou, B., additional, Alric, L., additional, Metivier, S., additional, Selves, J., additional, Larroquette, F., additional, Rio, V., additional, Haudebourg, J., additional, Saint-Paul, M.C., additional, De Monte, A., additional, Giordanengo, V., additional, Partouche, C., additional, Martin, A., additional, Ziol, M., additional, Baazia, Y., additional, Iwaka-Bande, V., additional, Gerber, A., additional, Uzan, M., additional, Garipuy, D., additional, Ferro-Collados, M.J., additional, Nicot, F., additional, Yazdanpanah, Y., additional, Adle-Biassette, H., additional, Alexandre, G., additional, Molina, J.M., additional, Bertheau, P., additional, Chaix, M.L., additional, Delaugerre, C., additional, Maylin, S., additional, Bottero, J., additional, Krause, J., additional, Girard, P.M., additional, Wendum, D., additional, Cervera, P., additional, Adam, J., additional, Viala, C., additional, Vittecocq, D., additional, Quertainmont, Y., additional, Teicher, E., additional, Pallier, C., additional, Lortholary, O., additional, Rouzaud, C., additional, Lourenco, J., additional, Touam, F., additional, Louisin, C., additional, Avettand-Fenoel, V., additional, Gardiennet, E., additional, Mélard, A., additional, Ochoa, A., additional, Blanchard, E., additional, Castet-Lafarie, S., additional, Cazanave, C., additional, Malvy, D., additional, Dupon, M., additional, Dutronc, H., additional, Dauchy, F., additional, Lacaze-Buzy, L., additional, Desclaux, A., additional, Bioulac-Sage, P., additional, Reigadas, S., additional, Lacoste, D., additional, Bonnet, F., additional, Bernard, N., additional, Hessamfar, J, M., additional, Paccalin, F., additional, Martell, C., additional, Pertusa, M.C., additional, Vandenhende, M., additional, Mercié, P., additional, Pistone, T., additional, Receveur, M.C., additional, Méchain, M., additional, Duau, P., additional, Rivoisy, C., additional, Faure, I., additional, Caldato, S., additional, Bellecave, P., additional, Tumiotto, C., additional, Pellegrin, J.L., additional, Viallard, J.F., additional, Lazzaro, E., additional, Greib, C., additional, Majerholc, C., additional, Brollo, M., additional, Farfour, E., additional, Polo Devoto, J., additional, Kansau, I., additional, Chambrin, V., additional, Pignon, C., additional, Berroukeche, L., additional, Fior, R., additional, Martinez, V., additional, Abgrall, S., additional, Favier, M., additional, Deback, C., additional, Lévy, Y., additional, Dominguez, S., additional, Lelièvre, J.D., additional, Lascaux, A.S., additional, Melica, G., additional, Raffi, F., additional, Allavena, C., additional, Reliquet, V., additional, Boutoille, D., additional, Biron, C., additional, Lefebvre, M., additional, Hall, N., additional, Bouchez, S., additional, Rodallec, A., additional, Le Guen, L., additional, Hemon, C., additional, Peyramond, D., additional, Chidiac, C., additional, Ader, F., additional, Biron, F., additional, Boibieux, A., additional, Cotte, L., additional, Ferry, T., additional, Perpoint, T., additional, Koffi, J., additional, Zoulim, F., additional, Bailly, F., additional, Lack, P., additional, Maynard, M., additional, Radenne, S., additional, Amiri, M., additional, Valour, F., additional, Augustin-Normand, C., additional, Scholtes, C., additional, Le-Thi, T.T., additional, Chavanet, P., additional, Duong Van Huyen, M., additional, Buisson, M., additional, Waldner-Combernoux, A., additional, Mahy, S., additional, Binois, R., additional, Simonet-Lann, A.L., additional, Croisier-Bertin, D., additional, Salmon Rousseau, A., additional, Martins, C., additional, Galim, S., additional, Lambert, D., additional, Nguyen, Y., additional, Berger, J.L., additional, Hentzien, M., additional, Brodard, V., additional, Partisani, M., additional, Batard, M.L., additional, Cheneau, C., additional, Priester, M., additional, Bernard-Henry, C., additional, de Mautort, E., additional, Gantner et S Fafi-Kremer, P., additional, Roustant, F., additional, Platterier, P., additional, Kmiec, I., additional, Traore, L., additional, Lepuil, S., additional, Parlier, S., additional, Sicart-Payssan, V., additional, Bedel, E., additional, Anriamiandrisoa, S., additional, Pomes, C., additional, Mole, M., additional, Bolliot, C., additional, Catalan, P., additional, Mebarki, M., additional, Adda-Lievin, A., additional, Thilbaut, P., additional, Ousidhoum, Y., additional, Makhoukhi, F.Z., additional, Braik, O., additional, Bayoud, R., additional, Gatey, C., additional, Pietri, M.P., additional, Le Baut, V., additional, Ben Rayana, R., additional, Bornarel, D., additional, Chesnel, C., additional, Beniken, D., additional, Pauchard, M., additional, Akel, S., additional, Lions, C., additional, Ivanova, A., additional, Ritleg, A.-S., additional, Debreux, C., additional, Chalal, L., additional, Zelie, J., additional, Hue, H., additional, Soria, A., additional, Cavellec, M., additional, Breau, S., additional, Joulie, A., additional, Fisher, P., additional, Gohier, S., additional, Ogoudjobi, S., additional, Brochier, C., additional, Thoirain-Galvan, V., additional, Le Cam, M., additional, Chalouni, M., additional, Conte, V., additional, Dequae-Merchadou, L., additional, Desvallees, M., additional, Gilbert, C., additional, Gillet, S., additional, Knight, R., additional, Lemboub, T., additional, Marcellin, F., additional, Michel, L., additional, Mora, M., additional, Protopopescu, C., additional, Roux, P., additional, Tezkratt, S., additional, Barré, T., additional, Baudoin, M., additional, Santos, M., additional, Di Beo, V., additional, and Nishimwe, M., additional

Published
2020
Full Text
View/download PDF

22. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference

Author

Munteanu, M. Tiniakos, D. Anstee, Q. Charlotte, F. Marchesini, G. Bugianesi, E. Trauner, M. Romero Gomez, M. Oliveira, C. Day, C. Dufour, J.-F. Bellentani, S. Ngo, Y. Traussnig, S. Perazzo, H. Deckmyn, O. Bedossa, P. Ratziu, V. Poynard, T. Castille, J.-M. Langon, T. Lawlor, D. Marra, F. Sørensen, T. Tribelli, C. De Minicis, S. Burt, A.D. Gouw, A.S.H. Lackner, C. Schirmacher, P. Terracciano, L. Brain, J. Bury, Y. Cabibi, D. David, E. Losi, L. Montani, M. Pareja, M.J. Wendum, D. Wrba, F. Ziol, M. Thabut, D. Moussalli, J. Lebray, P. Rudler, M. Bismuth, F.I. Rosmorduc, O. Calmus, Y. Hartemann, A. Jacqueminet, S. Bruckert, E. Giral, P. Naveau, S. Perlemuter, G. Varsat, B. Mercadier, A. the FLIP Consortium the FibroFrance Group

Abstract

Background: Blood tests of liver injury are less well validated in non-alcoholic fatty liver disease (NAFLD) than in patients with chronic viral hepatitis. Aims: To improve the validation of three blood tests used in NAFLD patients, FibroTest for fibrosis staging, SteatoTest for steatosis grading and ActiTest for inflammation activity grading. Methods: We pre-included new NAFLD patients with biopsy and blood tests from a single-centre cohort (FibroFrance) and from the multicentre FLIP consortium. Contemporaneous biopsies were blindly assessed using the new steatosis, activity and fibrosis (SAF) score, which provides a reliable and reproducible diagnosis and grading/staging of the three elementary features of NAFLD (steatosis, inflammatory activity) and fibrosis with reduced interobserver variability. We used nonbinary-ROC (NonBinAUROC) as the main endpoint to prevent spectrum effect and multiple testing. Results: A total of 600 patients with reliable tests and biopsies were included. The mean NonBinAUROCs (95% CI) of tests were all significant (P < 0.0001): 0.878 (0.864–0.892) for FibroTest and fibrosis stages, 0.846 (0.830–0.862) for ActiTest and activity grades, and 0.822 (0.804–0.840) for SteatoTest and steatosis grades. FibroTest had a higher NonBinAUROC than BARD (0.836; 0.820–0.852; P = 0.0001), FIB4 (0.845; 0.829–0.861; P = 0.007) but not significantly different than the NAFLD score (0.866; 0.850–0.882; P = 0.26). FibroTest had a significant difference in median values between adjacent stage F2 and stage F1 contrarily to BARD, FIB4 and NAFLD scores (Bonferroni test P < 0.05). Conclusions: In patients with NAFLD, SteatoTest, ActiTest and FibroTest are non-invasive tests that offer an alternative to biopsy, and they correlate with the simple grading/staging of the SAF scoring system across the three elementary features of NAFLD: steatosis, inflammatory activity and fibrosis. © 2016 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd

Published
2016

24. Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate

Author

Emily J. Greenspan, Gérard Lambeau, Daniel W. Rosenberg, Carine M. Mounier, Wendum D, Fléjou Jf, Institut de pharmacologie moléculaire et cellulaire (IPMC), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS), Trafic Membranaire et Signalisation Dans les Cellules Epitheliales, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche Saint-Antoine (UMRS893), Center for Molecular Medicine, University of Connecticut (UCONN), and Université Nice Sophia Antipolis (1965 - 2019) (UNS)

Subjects
Male, Cancer Research, Pathology, Colorectal cancer, Gene Expression, Polymerase Chain Reaction, 0302 clinical medicine, MESH: Aged, 80 and over, Intestinal mucosa, MESH: Colitis, MESH: Up-Regulation, MESH: Group III Phospholipases A2, Intestinal Mucosa, MESH: Aged, Aged, 80 and over, 0303 health sciences, MESH: Middle Aged, secreted phospholipase A2, MESH: Phospholipases A2, Secretory, Group III Phospholipases A2, Middle Aged, Colitis, Immunohistochemistry, 3. Good health, Up-Regulation, qPCR, Real-time polymerase chain reaction, Oncology, colon cancer, 030220 oncology & carcinogenesis, Colonic Neoplasms, MESH: Intestinal Mucosa, Biomarker (medicine), Adenocarcinoma, biomarker, Female, Adult, medicine.medical_specialty, MESH: Gene Expression, Colon, [SDV.CAN]Life Sciences [q-bio]/Cancer, Biology, 03 medical and health sciences, Survivin, medicine, Biomarkers, Tumor, Humans, Matrilysin, MESH: Colon, Phospholipases A2, Secretory, Molecular Diagnostics, 030304 developmental biology, Aged, MESH: Colonic Neoplasms, MESH: Humans, MESH: Adenocarcinoma, Cancer, MESH: Adult, MESH: Immunohistochemistry, MESH: Polymerase Chain Reaction, medicine.disease, MESH: Male, MESH: Tumor Markers, Biological, Cancer research, MESH: Female, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Recent studies suggest that secreted phospholipases A2 (sPLA2s) represent attractive potential tumour biomarkers and therapeutic targets for various cancers. As a first step to address this issue in human colorectal cancer, we examined the expression of the full set of sPLA2s in sporadic adenocarcinomas and normal matched mucosa from 21 patients by quantitative PCR and immunohistochemistry. In normal colon, PLA2G2A and PLA2G12A were expressed at high levels, PLA2G2D, PLA2G5, PLA2G10 and PLA2G12B at moderate levels, and PLA2G1B, PLA2G2F and PLA2G3 at low levels. In adenocarcinomas from left and right colon, the expression of PLA2G3 was increased by up to 40-fold, while that of PLA2G2D and PLA2G5 was decreased by up to 23- and 14-fold. The variations of expression for sPLA2-IID, sPLA2-III and sPLA2-V were confirmed at the protein level. The expression pattern of these sPLA2s appeared to be linked respectively to the overexpression of interleukin-8, defensin alpha6, survivin and matrilysin, and downregulation of SFRP-1 and RLPA-1, all these genes being associated to colon cancer. This original sPLA2 profile observed in adenocarcinomas highlights the potential role of certain sPLA2s in colon cancer and suggests that sPLA2-III might be a good candidate as a novel biomarker for both left and right colon cancers.

Published
2008

26. Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH)

Author

Carrieri, Maria Patrizia, Serfaty, Lawrence, Vilotitch, Antoine, Poizot-Martin, Isabelle, Loko, Marc-Arthur, Lions, Caroline, Salmon-Ceron, Dominique, Spire, Bruno, Dabis, François, Salmon, D, Dabis, F, Winnock, M, Sogni, P, Benhamou, Y, Trimoulet, P, Izopet, J, Paradis, V, Spire, B, Carrieri, P, Katlama, C, Pialoux, G, Valantin, M A, Bonnard, P, Rosenthal, E, Garipuy, D, Bouchaud, O, Gervais, A, Lascoux-Combe, C, Goujard, C, Lacombe, K, Duvivier, C, Vittecoq, D, Neau, D, Morlat, P, Banisadr, F, Meyer, L, Boufassa, F, Dominguez, S, Autran, B, Roque, a M, Solas, C, Fontaine, H, Serfaty, L, Chêne, G, Costagliola, D, Zucman, D, Simon, A, Billaud, E, Miailhes, P, Devoto, J Polo, Couffin-Cadiergues, S, Mehawej, H, Makhlouf, Z, Dubost, G, Tessier, F, Gibault, L, Beuvon, F, Chambon, E, Lazure, T, Krivine, A, Charlotte, F, Fourati, S, Cacoub, P, Nafissa, S, Zaegel, O, Ménard, A, Geneau, P, Tamalet, C, Bani-Sadr, F, Slama, L, Lyavanc, T, Callard, P, Bendjaballah, F, Le-Pendeven, C, Marchou, B, Alric, Laurent, Barange, K, Metivier, S, Fooladi, A, Selves, J, Nicot, F, Durant, J, Haudebourg, J, Saint-Paul, M C, Ziol, M, Baazia, Y, Uzan, M, Bicart-See, A, Ferro-Collados, M J, Yéni, P, Adle-Biassette, H, Molina, J M, Combe, C Lascoux, Bertheau, P, Duclos, J, Palmer, P, Girard, P M, Campa, P, Wendum, D, Cervera, P, Adam, J, Harchi, N, Delfraissy, J F, Quertainmont, Y, Pallier, C, Lortholary, O, Shoai-Tehrani, M, Lacaze-Buzy, L, Caldato, S, Bioulac-Sage, P, Reigadas, S, Majerholc, C, Guitard, F, Boue, F, Kansau, I, Chambrin, V, Pignon, C, Berroukeche, L, Fior, R, Martinez, V, Deback, C, Lévy, Y, Lelièvre, J D, Lascaux, a S, Melica, G, Raffi, F, Alavena, C, Rodallec, A, Peyramond, D, Chidiac, C, Ader, F, Biron, F, Boibieux, A, Cotte, L, Ferry, T, Perpoint, T, Koffi, J, Zoulim, F, Bailly, F, Lack, P, Radenne, S, Amiri, M, Beniken, D, Ritleng, a S, Azar, M, Honoré, P, Breau, S, Joulie, A, Mole, M, Bolliot, C, Chouraqui, F, Touam, F, André, F, Ouabdesselam, N, Partouche, C, Alexandre, G, Ganon, A, Champetier, A, Hue, H, Brosseau, D, Brochier, C, Thoirain, V, Rannou, M, Bornarel, D, Gillet, S, Delaune, J, Pambrun, E, Dequae-Merchadou, L, Frosch, A, Maradan, G, Cheminat, O, Marcellin, F, Mora, M, Protopopescu, C, Aix Marseille Université (AMU), Pathologies biliaires, fibrose et cancer du foie [CRSA], Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Epidemiologie-Biostatistique [Bordeaux], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux Ségalen [Bordeaux 2], AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Pathologies biliaires, fibrose et cancer du foie [CHU Saint-Antoine], Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), and Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)

Subjects
cannabis, Microbiology (medical), Adult, Male, medicine.medical_specialty, Marijuana Abuse, [SDV]Life Sciences [q-bio], Population, HIV Infections, Risk Assessment, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Surveys and Questionnaires, cohort study, medicine, Humans, 030212 general & internal medicine, Longitudinal Studies, education, education.field_of_study, biology, business.industry, Confounding, HIV, Odds ratio, Hepatitis C, Chronic, Middle Aged, biology.organism_classification, Confidence interval, 3. Good health, Infectious Diseases, Endocrinology, HCV, Cohort, Homeostatic model assessment, 030211 gastroenterology & hepatology, Female, Cannabis, France, Insulin Resistance, business, Cohort study
Abstract

International audience; Diabetes and insulin resistance (IR) is common in human immunodeficiency virus-hepatitis C virus (HIV-HCV)-coinfected patients, a population also concerned with elevated cannabis use. Cannabis has been associated with reduced IR risk in some population-based surveys. We determined whether cannabis use was consistently associated with reduced IR risk in HEPAVIH, a French nationwide cohort of HIV-HCV-coinfected patients.Methods: HEPAVIH medical and sociobehavioral data were collected (using annual self-administered questionnaires). We used 60 months of follow-up data for patients with at least 1 medical visit where IR (using homeostatic model assessment of insulin resistance [HOMA-IR]) and cannabis use were assessed. A mixed logistic regression model was used to evaluate the association between IR risk (HOMA-IR > 2.77) and cannabis use (occasional, regular, daily).Results: Among the 703 patients included in the study (1287 visits), 323 (46%) had HOMA-IR > 2.77 for at least 1 follow-up visit and 319 (45%) reported cannabis use in the 6 months before the first available visit. Cannabis users (irrespective of frequency) were less likely to have HOMA-IR > 2.77 (odds ratio [95% confidence interval], 0.4 [.2-.5]) after adjustment for known correlates/confounders. Two sensitivity analyses with HOMA-IR values as a continuous variable and a cutoff value of 3.8 confirmed the association between reduced IR risk and cannabis use.Conclusions: Cannabis use is associated with a lower IR risk in HIV-HCV-coinfected patients. The benefits of cannabis-based pharmacotherapies for patients concerned with increased risk of IR and diabetes need to be evaluated in clinical research and practice.

Published
2014

27. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease

Author

Bedossa, P. Burt, D.A. Gouw, S.H.A. Lackner, C. Schirmacher, P. Terracciano, L. Tiniakos, D. Brain, J. Bury, Y. Cabibi, D. Charlotte, F. David, E. Losi, L. Montani, M. Pareja, M.J. Wendum, D. Ziol, M. Ratziu, V.

Abstract

Biopsy is still the gold standard for the diagnosis of nonalcoholic steatohepatitis but the definition may vary among pathologists, a drawback especially in evaluation of biopsies for clinical trials. We previously developed a scoring system (steatosis, activity, fibrosis [SAF]) allowing the use of an algorithm (fatty liver inhibition of progression [FLIP]) for the classification of liver injury in morbid obesity. The aim of this study was to determine whether the use of the SAF score and FLIP algorithm can decrease interobserver variations among pathologists. In a first session, pathologists categorized 40 liver biopsies of patients with nonalcoholic fatty liver disease (NAFLD) according to their own experience. In a second reading session, each pathologist reclassified the same slides by using the FLIP algorithm and SAF score, blinded to their first evaluation. The experiment was repeated with two different groups of pathologists at varying levels of training in liver pathology. The percentage of biopsy interpretation concordant with reference evaluation increased from 77% to 97% in Group 1 and from 42% to 75% in Group 2 after the use of the SAF score and FLIP algorithm. The strength of concordance in classification increased in Group 1 from moderate (κ=0.54) to substantial (κ=0.66) and from fair (κ=0.35) to substantial (κ=0.61) in Group 2 with application of the algorithm. With regard to the SAF score, concordance was substantial in Group 1 for steatosis (κ=0.61), activity (κ=0.75), and almost perfect for fibrosis (κ=0.83 after pooling 1a, 1b, and 1c together into a single score F1). Similar trends were observed in Group 2 (κ=0.54 for S, κ=0.68 for A, and κ=0.72 for F). Conclusion: The FLIP algorithm based on the SAF score should decrease interobserver variations among pathologists and are likely to be implemented in pathology practice. (Hepatology 2014;60:565-575) © 2014 by the American Association for the Study of Liver Diseases.

Published
2014

29. Validation of the Prognostic Value of Histologic Scoring Systems in Primary Sclerosing Cholangitis; A Multicenter Cohort Study

Author

De Vries, E., primary, Verheij, J., additional, Farkkila, M., additional, Arola, J., additional, Goeppert, B., additional, Schirmacher, P., additional, Gotthardt, D., additional, Trivedi, P., additional, Hirschfield, G., additional, Ytting, H., additional, Vainer, B., additional, Harms, M., additional, van Buuren, H., additional, Biermann, K., additional, Chazouillers, O., additional, Wendum, D., additional, Williamson, K., additional, Chapman, R., additional, Wang, L.M., additional, Hubscher, S., additional, and Ponsioen, C., additional

Published
2016
Full Text
View/download PDF

30. Nosology and Molecular Classification of Hepatocellular Adenomas

Author

Nault, J.C., primary, Couchy, G., additional, Bioulac-Sage, P., additional, Bacq, Y., additional, Calderaro, J., additional, Paradis, V., additional, Ramos, J., additional, Scoazec, J.-Y., additional, Leteurtre, E., additional, Sturm, N., additional, Guettier, C., additional, Fabre, M., additional, Savier, E., additional, Chiche, L., additional, Labrune, P., additional, Selves, J., additional, Wendum, D., additional, Morcrette, G., additional, Gelabale, E., additional, Pilati, C., additional, Laurent, A., additional, De Muret, A., additional, Blanc, J.-F., additional, Le Bail, B., additional, Imbeaud, S., additional, Balabaud, C., additional, Rebouissou, S., additional, and Zucman-Rossi, J., additional

Published
2016
Full Text
View/download PDF

33. P1148 : Long-term administration of ursodeoxycholic acid prevents recurrence of primary biliary cirrhosis after liver transplantation

Author

Bosch, A., primary, Dumortier, J., additional, Maucor Boulch, D., additional, Conti, F., additional, Morard, I., additional, Rubbia-Brandt, L., additional, Scoazec, J.-Y., additional, Wendum, D., additional, Terris, B., additional, Boillot, O., additional, Radenne, S., additional, Chazouillères, O., additional, Calmus, Y., additional, Giostra, E., additional, and Corpechot, C., additional

Published
2015
Full Text
View/download PDF

37. P48 EGF/EGFR AXIS CONTRIBUTES TO THE PROGRESSION OF CHOLANGIOCARCINOMA THROUGH THE INDUCTION OF AN EPITHELIAL–MESENCHYMAL TRANSITION

Author

Clapéron, A., primary, Mergey, M., additional, Ho-Bouldoires, T.H. Nguyen, additional, Vignjevic, D., additional, Wendum, D., additional, Chrétien, Y., additional, Merabtene, F., additional, Frazao, A., additional, Paradis, V., additional, Housset, C., additional, Guedj, N., additional, and Fouassier, L., additional

Published
2014
Full Text
View/download PDF

40. N-terminal and C-terminal plasma membrane anchoring modulate differently agonist-induced activation of cytosolic phospholipase A2

Author

Klapisz, E., Ziari, M., Wendum, D., Koumanov, K., Brachet-Ducos, C., Olivier, J. L., Béréziat, G., Trugnan, G., Masliah, J., CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de Recherche Saint-Antoine (UMRS893), and Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
MESH: Enzyme Activation, Recombinant Fusion Proteins, Molecular Sequence Data, MESH: Cricetinae, MESH: Amino Acid Sequence, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, CHO Cells, In Vitro Techniques, Phospholipases A, Mice, Cytosol, MESH: Cytosol, MESH: CHO Cells, Cricetinae, MESH: Recombinant Fusion Proteins, Animals, Humans, MESH: Animals, Amino Acid Sequence, MESH: Mice, MESH: Phospholipases A2, Conserved Sequence, MESH: Lymphocyte Specific Protein Tyrosine Kinase p56(lck), MESH: Humans, MESH: Molecular Sequence Data, MESH: Conserved Sequence, Arachidonic Acid, Binding Sites, MESH: Molecular Weight, Cell Membrane, MESH: Arachidonic Acid, Enzyme Activation, Molecular Weight, Phospholipases A2, MESH: Binding Sites, Lymphocyte Specific Protein Tyrosine Kinase p56(lck), ras Proteins, MESH: Phospholipases A, MESH: ras Proteins, MESH: Cell Membrane
Abstract

International audience; The 85 kDa cytosolic phospholipase A2 (cPLA2) plays a key role in liberating arachidonic acid from the sn-2 position of membrane phospholipids. When activated by extracellular stimuli, cPLA2 undergoes calcium-dependent translocation from cytosol to membrane sites which are still a matter of debate. In order to evaluate the effect of plasma membrane association on cPLA2 activation, we constructed chimeras of cPLA2 constitutively targeted to the plasma membrane by the N-terminal targeting sequence of the protein tyrosine kinase Lck (Lck-cPLA2) or the C-terminal targeting signal of K-Ras4B (cPLA2-Ras). Constitutive expression of these chimeras in Chinese hamster ovary cells overproducing the alpha2B adrenergic receptor (CHO-2B cells) did not affect the basal release of [3H]arachidonic acid, indicating that constitutive association of cPLA2 with cellular membranes did not ensure the hydrolysis of membrane phospholipids. However, Lck-cPLA2 increased [3H]arachidonic acid release in response to receptor stimulation and to increased intracellular calcium, whereas cPLA2-Ras inhibited it, compared with parental CHO-2B cells and CHO-2B cells producing comparable amounts of recombinant wild-type cPLA2. The lack of stimulation of cPLA2-Ras was not due to a decreased enzymatic activity as measured using an exogenous substrate, or to a decreased phosphorylation of the protein. These results show that the plasma membrane is a suitable site for cPLA2 activation when orientated correctly.

Published
1999

41. Hydatid cyst

Author

Décarie, P.-O., primary, Wendum, D., additional, Cazejust, J., additional, and Arrivé, L., additional

Published
2013
Full Text
View/download PDF

43. Cirrhose biliaire primitive : définition et analyse des variations inter-observateurs d’un score histologique pour les biopsies hépatiques prenant en compte les lésions d’intérêt pronostique

Author

Wendum, D., primary, Boëlle, P.-Y., additional, Bedossa, P., additional, Zafrani, E.S., additional, Charlotte, F., additional, Saint-Paul, M.-C., additional, Michalak, S., additional, Chazouillères, O., additional, and Corpechot, C., additional

Published
2012
Full Text
View/download PDF

44. Fibrose hépatique

Author

Lemoinne, S., primary, Cadoret, A., additional, Bosselut, N., additional, Housset, C., additional, Wendum, D., additional, and Thabut, D., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results